Contraindicated in:
Use Cautiously in:
CV: hypertension, hypotension, palpitations, syncope, tachycardia.
Derm: facial flushing.
EENT: dry mouth.
GI: abdominal pain, nausea, vomiting.
Neuro: anxiety, concentration difficulty, confusion, dizziness, drowsiness, mood change, abnormal thinking, amnesia, ataxia, depression, disorientation, euphoria, hallucinations, headache, impaired judgment, paranoia, paresthesia, SEIZURES.
Misc: physical dependence, psychological dependence (high doses or prolonged therapy).
Drug-Drug:
Drug-Natural Products:
Drug-Food:
(Generic available)
Nausea and Vomiting Associated with Cancer Chemotherapy
Anorexia Associated with Weight Loss in AIDS
Absorption: Extensively metabolized following absorption, resulting in poor bioavailability (1020%).
Distribution: Enters breast milk in high concentrations. Highly lipid-soluble. Persists in tissues for prolonged period of time.
Protein Binding: 97%.
Metabolism/Excretion: Primarily metabolized in the liver via the CYP2C9 isoenzyme with some metabolism by the CYP3A4 isoenzyme; the CYP2C9 enzyme system exhibits genetic polymorphism; poor metabolizers may have significantly ↑ dronabinol concentrations and an ↑ risk of adverse effects; 50% excreted via biliary elimination. At least one metabolite is psychoactive.
Half-life: 2536 hr.
Schedule II (C-II)(oral solution)
Schedule III (C-III)(capsules)
NDC Code*